Page last updated: 2024-09-03

vadimezan and Lymphoma

vadimezan has been researched along with Lymphoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berg, RW; Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Sun, X; Yang, Y	1
Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Pandey, S	1

Other Studies

2 other study(ies) available for vadimezan and Lymphoma

Article	Year
Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer gene therapy, 2003, Volume: 10, Issue:6 Topics: Animals; CD8-Positive T-Lymphocytes; Cell Adhesion; COS Cells; Cytoplasm; DNA, Complementary; Flow Cytometry; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Immunotherapy; Intercellular Adhesion Molecule-1; Killer Cells, Natural; Leukocytes; Lymphoma; Mice; Mutation; Neoplasms; Plasmids; Protein Structure, Tertiary; Signal Transduction; Time Factors; Transfection; Transgenes; Xanthones	2003
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer research, 2001, Mar-01, Volume: 61, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Flavonoids; Gene Dosage; Genetic Therapy; Genetic Vectors; Immunotherapy; Killer Cells, Natural; Lymphocyte Subsets; Lymphoma; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; T-Lymphocytes, Cytotoxic; Thymus Neoplasms; Xanthenes; Xanthones	2001

Article

Year

Requirements for ICAM-1 immunogene therapy of lymphoma.

Cancer gene therapy, 2003, Volume: 10, Issue:6

Topics: Animals; CD8-Positive T-Lymphocytes; Cell Adhesion; COS Cells; Cytoplasm; DNA, Complementary; Flow Cytometry; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Immunotherapy; Intercellular Adhesion Molecule-1; Killer Cells, Natural; Leukocytes; Lymphoma; Mice; Mutation; Neoplasms; Plasmids; Protein Structure, Tertiary; Signal Transduction; Time Factors; Transfection; Transgenes; Xanthones

2003

Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.

Cancer research, 2001, Mar-01, Volume: 61, Issue:5

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Flavonoids; Gene Dosage; Genetic Therapy; Genetic Vectors; Immunotherapy; Killer Cells, Natural; Lymphocyte Subsets; Lymphoma; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; T-Lymphocytes, Cytotoxic; Thymus Neoplasms; Xanthenes; Xanthones

2001